Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   3388 News 


«12...1920212223242526272829...4849»
  • ||||||||||  cefepime hydrochloride / Generic mfg.
    Clinical Outcomes with Carbapenem-Resistant Pseudomonas Aerugionsa Pneumonia Treated with Cefepime (Exhibit and Poster Hall) -  May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_1556;    
    Patients treated with cefepime were compared to other active therapies (polymyxin, ceftolozane-tazobactam, ceftazidime-avibactam, and ciprofloxacin). For the treatment of CRPA pneumonia, cefepime had similar clinical outcomes when compared to other active therapies.
  • ||||||||||  Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD)
    Pseudomonas Aeruginosa Infections Treated with Imipenem-Cilastatin-Relebactam (Exhibit and Poster Hall) -  May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_1470;    
    In this small case series of patients, I-R was used to treat MDR Pseudomonas aeruginosa infections from a primarily respiratory source that often recur. These infections were highly resistant to novel antibiotics.
  • ||||||||||  Overcoming β-Lactam and Multi-Drug Resistance in Pseudomonas Aeruginosa Through a Novel β-Lactam/β-Lactam Enhancer Combination: A Step Beyond β-Lactam/β-Lactamase Inhibitors (Salon GHI) -  May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_241;    
    MICs of cefepime/zidebactam (FEP/ZID, a BL/BLE) and novel BL/BLIs were determined against a selected panel (n=113) of MDR PSA...Among the subset of non-carbapenemase producing strains (79/113), susceptibilities (CLSI criteria) to ceftolozane/tazobactam, cefepime/taniborbactam, ceftazidime/avibactam, and imipenem/relebactam were 54, 52, 51, and 61%, respectively while FEP/ZID, inhibited 92.4% at 8 mg/L...The BL/BLE, FEP/ZID combination demonstrated comprehensive activity in vitro and translational in vivo efficacy against strains with FEP/ZID MICs up to 32 mg/L (a concentration inhibiting 100% of PSAs). BLE mechanism of FEP/ZID potentially offers a novel paradigm in managing infections caused by present and future MDR PSA clones.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    SUCCESSFULLY TREATED CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) INVASIVE INFECTIONS IN A PEDIATRIC INTENSIVE CARE UNIT () -  May 19, 2022 - Abstract #ESPID2022ESPID_1156;    
    Due to persistently positive BLC, inhaled colistin was tried, with good response...Its treatment is challenging due to limited antibiotic options and scarceness of studies on therapeutic effectiveness in pediatrics. Bearing in mind the resistance emergence, the use of ceftazidime-avibactam and tigecycline must be rational but it is encouraging in terms of clinical response and survival.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    PATTERNS AND TRENDS OF ANTIMICROBIAL USE IN A PEDIATRIC INTENSIVE CARE UNIT (PICU) USING DAYS OF THERAPY () -  May 19, 2022 - Abstract #ESPID2022ESPID_831;    
    Total consumption of antimicrobials had a median monthly rate (MMR) 259 DOTs/100BD. Glycopeptides (vancomycin/teicoplanin) constituted the most common used antimicrobial class (40 DOT/100BD) but showed a significant decrease during the last 4 months of the study.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    IMPACT OF EARLY FEVER ONSET AND NOVEL ANTIBIOTICS PROLONGED FEBRILE NEUTROPENIA OUTCOME FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION. SINGLE CENTER 10-YEAR RETROSPECTIVE STUDY () -  May 13, 2022 - Abstract #EHA2022EHA_1580;    
    Median treatment line prior to ASCT was two (range 1-5) with 42 patients being in first line, while around 40% was treated with rituximab previously...Fever duration was impacted by ceftolozane/tazobactam and ceftazidime/avibactam treatment (p=0.04), and documented infection site on CT scan (p=0.009). Finally, prolonged fever duration was associated early fever onset following ASCT [Figure 1B] and number of days with CRP greater than 10 mg/dL using Spearman correlation analysis...Clinical and laboratory characteristics, such as early fever onset following ASCT, can be of aid in identifying potentially life-threatening infections. The availability of novel antibiotics could improve the outcome in this setting of patients.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA MENINGOENCEPHALITIS IN AN INFANT TREATED WITH CEFIDEROCOL () -  May 12, 2022 - Abstract #ESPID2022ESPID_805;    
    Intravenous (IV) vancomycin, amikacin, and meropenem were started as empirical treatment and two external ventricular drains were inserted...Susceptibility tests showed resistance to piperacillin-tazobactam, cephalosporins, meropenem (MIC > 8 ug/mL), ceftazidime-avibactam, aminoglycosides, quinolones, and susceptibility to colistin...Secondly, considering in vitro synergistic activity of colistin and aztreonam, the latter was added to therapy...In this case, the negativization of CSF cultures and the radiological improvement coincided with the start of cefiderocol. Further studies are required to determine the pharmacokinetics and pharmacodynamics of cefiderocol in the pediatric population, as well as to define the most appropriate dose, duration of treatment, and combination therapy in case of MDR severe infections.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis. (Pubmed Central) -  May 10, 2022   
    This report adds to the growing literature that phage therapy may be a safe and effective approach to augment antibiotic therapy for patients infected with drug-resistant pathogens. Furthermore, it highlights the importance of the GES β-lactamase family in contributing to inactivation of a broad range of β-lactam antibiotics in P. aeruginosa, including ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Trial completion date, Trial primary completion date, Gram negative:  NOOR: Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants. (clinicaltrials.gov) -  May 9, 2022   
    P2a,  N=48, Recruiting, 
    Furthermore, it highlights the importance of the GES β-lactamase family in contributing to inactivation of a broad range of β-lactam antibiotics in P. aeruginosa, including ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam. Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Review, Journal:  Ceftazidime-avibactam. (Pubmed Central) -  May 7, 2022   
    Compared to carbapenems, ceftazidime-avibactam has demonstrated non-inferiority in the treatment of nosocomial pneumonia including better clinical and microbiological cure rates and mortality compared to colistin. The limitation of ceftazidime-avibactam in the treatment of infections caused by metallo-beta-lactamase-producing Enterobacteriaceae can be overcome with the addition of aztreonam.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal:  In vitro activity of cefiderocol against Gram-negative pathogens in Germany. (Pubmed Central) -  May 6, 2022   
    Cefiderocol exhibited consistently high in vitro activity against a variety of GNB isolates collected in Germany, including resistant phenotypes, across multiple infection sites. These data suggest that cefiderocol is an effective choice of antibacterial agent in patients with GNB infection, regardless of species and resistance phenotype to other agents.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal:  In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates (Pubmed Central) -  May 5, 2022   
    Colistin, tigecycline and aminoglycosides are almost the only and last choice antibiotics in the treatment of infections caused by carbapenem-resistant Enterobacterales members...The minimum inhibitory concentration (MIC) values of the isolates for meropenem, colistin, ceftazidime, and ceftazidime-avibactam were determined by broth microdilution method...To prevent the development of resistance which is observed even in last-choice therapeutic antibiotics, the principles of rational antibiotic use should be followed. The appropriate antimicrobial susceptibility testing should be routinely performed for surveillance of ceftazidime-avibactam and colistin.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Multicenter Genomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae from Bacteremia in China. (Pubmed Central) -  Apr 30, 2022   
    We detected virulence markers among multidrug resistant strains, and a high number of genetically similar isolates, suggesting intra-hospital transmission within single and multiple wards. Reducing intra-hospital transmission remains to be the key to control CRKP caused bacteremia in China.